National Asset Management, Inc. Intellia Therapeutics, Inc. Transaction History

National Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$58.27 - $118.99 $153,308 - $313,062	-2,631 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$100.76 - $138.36 $43,427 - $59,633	-431 Reduced 14.08%	2,631 $312,000
Q3 2021 Nov 16, 2021	SELL	$132.37 - $176.78 $49,374 - $65,938	-373 Reduced 10.86%	3,062 $423,000
Q2 2021 Aug 10, 2021	BUY	$60.88 - $161.91 $35,188 - $93,583	578 Added 20.23%	3,435 $557,000
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $133,107 - $239,073	2,857 New	2,857 $230,000

316

91.7M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.